v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue:    
Grant and contract revenue $ 538,645 $ 901,880
Operating expenses:    
Research and development 3,406,248 2,782,506
General and administrative 4,767,645 3,270,548
Goodwill impairment loss 0  
Change in fair value of contingent consideration 6,000 (27,000)
Total operating expenses 8,179,893 6,026,054
Loss from operations (7,641,248) (5,124,174)
Change in fair value of warrant liability (8,702) (977,710)
Investor relations expense   (66,767)
Interest income 195,165 52,710
Other expense, net (168,355) (257,479)
Total non-operating income (loss) 18,108 (1,249,246)
Net loss before income taxes (7,623,140) (6,373,420)
Net loss (7,623,140) (6,373,420)
Net loss - non-controlling interest (90,962) (81,314)
Net loss attributable to Heat Biologics, Inc. $ (7,532,178) $ (6,292,106)
Net loss per share, basic and diluted $ (0.31) $ (0.77)
Weighted-average common shares outstanding, basic and diluted 24,199,916 8,183,154
Comprehensive loss:    
Net loss $ (7,623,140) $ (6,373,420)
Unrealized gain on foreign currency translation 18,268 218,804
Total comprehensive loss (7,604,872) (6,154,616)
Comprehensive loss attributable to non-controlling interest (90,962) (81,314)
Comprehensive loss - Heat Biologics, Inc. $ (7,513,910) $ (6,073,302)

Source